Insider transactions

Richard William Scalzo

CIK 1789545 · Chief Financial Officer · last filed 2026-09-18

Richard William Scalzo is a Chief Financial Officer who has filed 65 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider sold $10.2K of GLYC on Sep 18, 2026. Across all open-market trades the lifetime net is −$8.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.8M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$1.85M
Companies
2
Total Filings
65
Lifetime Open-Market Net
-$8.74M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
25 ALBERTA LANE
HOLLISTON, MA 01746
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CRESCENT BIOPHARMA, INC. (GLYC) Delisted Chief Financial Officer 19,730 $15.70 $309.8K -$30.2K 3 2026-09-18
DYN SVP, Head of Finance & Admin. 122,330 $15.10 $1.85M -$8.71M 35 2025-03-13

Recent Filings

65 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-18 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Sell (S) −568 -$10.2K EDGAR
2026-06-23 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Sell (S) −1,112 -$20.0K EDGAR
2025-12-17 CRESCENT BIOPHARMA, INC. (GLYC) Delisted Grant (A) +19,422 $0 EDGAR
2025-06-11 DYN Notice (144) −1,330 -$19.6K EDGAR
2025-06-05 DYN Notice (144) −914 -$12.2K EDGAR
2025-05-16 DYN Notice (144) −2,479 -$29.3K EDGAR
2025-03-13 DYN Sell (S) −1,343 -$15.3K EDGAR
2025-03-11 DYN Notice (144) −1,343 -$15.3K EDGAR
2025-03-07 DYN Sell (S) −917 -$10.8K EDGAR
2025-03-05 DYN Notice (144) −915 -$10.9K EDGAR
Showing 1–10 of 65
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.